Skip to main content

SI-BONE, Inc. Announces iFuse Bedrock Granite® Implant System Compatibility with Certain Medtronic CD Horizon® Solera® 5.5/6.0 System Rods

Written by Customer Service on . Posted in Public Companies.

SANTA CLARA, Calif., Sept. 05, 2023 (GLOBE NEWSWIRE) — SI-BONE, Inc. (Nasdaq: SIBN), a Silicon Valley-based medical device company focused on sacropelvic surgical solutions, today confirmed that certain CD Horizon® Solera® 5.5mm and 6.0mm posterior spinal fixation rods manufactured by Medtronic Sofamor Danek USA Inc., a division of Medtronic plc, meet SI-BONE’s criteria for compatibility with iFuse Bedrock Granite® indicated in the Granite implant’s instructions for use. A complete list of Medtronic Solera® rods meeting the criteria for compatibility described in Granite’s cleared labeling is available on SI-BONE’s website at: http://www.si-bone.com/granite-implant-solera-compatbibility-criteria.

“Given the strong initial reception for Granite, we are thrilled to confirm that a number of Medtronic’s Solera® rods, used by many spine surgeons, meet Granite’s compatibility criteria,” said Laura Francis, CEO of SI-BONE. “Our existing general rod compatibility clearance, along with confirmation that these Medtronic Solera® rods meet the criteria for compatibility with the Granite implant will give spine surgeons additional confidence in using our leading pelvic fixation implant with the Medtronic Solera® system.”

The iFuse Bedrock Granite implant was cleared by FDA on May 26, 2022. FDA recognized the Granite implant’s significant advantages over existing approved or cleared alternatives in designating the product as a Breakthrough Device. CMS subsequently adopted a New Technology Add-on Payment of up to $9,828 per procedure, based on the individual hospital’s costs, for procedures reimbursed under the Medicare program and incorporating this new technology.

About SI-BONE, Inc.
SI-BONE (NASDAQ: SIBN) is a global leader in technology for surgical treatment of musculoskeletal disorders of the sacropelvic anatomy. Since pioneering minimally invasive SI joint surgery in 2009, SI-BONE has supported over 3,000 surgeons in performing a total of over 80,000 sacropelvic procedures. A unique body of clinical evidence supports the use of SI-BONE’s technologies, including two randomized controlled trials and over 120 peer reviewed publications. SI-BONE has leveraged its leadership in minimally invasive SI joint fusion to commercialize novel solutions for adjacent markets, including adult deformity, spinopelvic fixation and pelvic trauma.

For additional information on the company or the products including risks and benefits, please visit www.si-bone.com. For the iFuse Bedrock Granite instructions for use, including indications for use and risk information, please visit www.si-bone.com/label.

SI-BONE and iFuse Bedrock Granite are registered trademarks of SI-BONE, Inc. Medtronic, CD Horizon and Solera are registered trademarks of Medtronic, Inc. and are used herein with the consent of Medtronic. ©2023 SI-BONE, Inc. All Rights Reserved.

Investor Contact:

Saqib Iqbal
Sr. Director, FP&A and Investor Relations
investors@SI-BONE.com

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.